Overall, our in vivo data indicated that mast cells and neutrophils, under activation by the tumor microenvironment, demonstrate up-regulation of ANXA1/FPR2 as an anti-inflammatory response mechanism to resolve inflammation and proliferation in laryngeal cancer. The gene discussed is ANXA1; the disease is laryngeal carcinoma.